All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Isolated Hepatic Perfusion With Melphalan Improves PFS, ORR for Patients With Isolated Uveal Melanoma Liver Metastases

March 24th 2023

A one-time treatment with isolated hepatic perfusion with melphalan improved median progression-free survival compared with best alternative treatment for patients with previously untreated isolated liver metastases from uveal melanoma.

FDA Issues Complete Response Letter for Ruxolitinib Extended-Release Tablets in MPNs

March 24th 2023

The FDA has issued a complete response letter for ruxolitinib extended-release tablets for use once daily in the treatment of patients with certain types of myelofibrosis, polycythemia vera, and graft-vs-host disease.

The American Cancer Society, Winship Partner to Accelerate Cancer Research in Georgia

March 24th 2023

The American Cancer Society, in partnership with Winship Cancer Institute of Emory University, announced a new project that aims to significantly accelerate cancer research and improve patient outcomes.

Delays in Cancer Screenings Due to COVID-19 May Result in Trend Toward Excess Deaths

March 24th 2023

Cancer screenings rapidly decreased during the COVID-19 pandemic as health care practices considered not urgent came to a halt.

Multiple Factors Need to Be Addressed to Improve Late Mortality for Survivors of Childhood Cancer

March 24th 2023

Matthew J. Ehrhardt, MD, MS, discusses the importance of taking a multifactorial approach to improve long-term outcomes for survivors of childhood cancer, and expands on the findings from the study of the factors associated with risk of late mortality.

Acalabrutinib Receives Approval in China for Relapsed/Refractory Mantle Cell Lymphoma

March 23rd 2023

Acalabrutinib has received conditional approval from the National Medical Products Administration in China for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy.

Research Clarifies Treatment Patterns and Raises New Questions Across GI Cancers

March 23rd 2023

Jimmy Hwang, MD, discusses findings supporting the use of immunotherapy in hepatocellular carcinoma and biliary tract cancer, the potential benefits of antibody-drug conjugates in metastatic colorectal cancer, and unmet needs in esophageal squamous cell carcinoma and rectal cancer.

Nationwide Initiative Aims to Address Disparities in Early-Phase Cancer Clinical Trials

March 23rd 2023

To expand access to cancer care and research, Stand Up To Cancer® has launched a 4-team initiative across the United States designed to fill in these gaps in care and remove barriers to entry.

Improved Understanding of Biomarkers in Tumor Microenvironment Key for Treatment Decisions in NSCLC

March 23rd 2023

Brian S. Henick, MD, discusses the importance of expanding on the current knowledge of biomarkers and the tumor microenvironment to enhance treatment approaches for patients with non–small cell lung cancer.

BET Inhibitors Plus Sunitinib Induce Early Signs of Clinical Activity in Melanoma Cells

March 23rd 2023

Sunitinib demonstrated synergistic activity with the BET inhibitors JQ1 and NHWD-870 in melanoma cell lines.

Cleveland Clinic Opens New Cancer Center in Abu Dhabi

March 23rd 2023

Cleveland Clinic has opened a new state-of-the-art cancer facility, named the Fatima bint Mubarak Center, at Cleveland Clinic Abu Dhabi.

Emerging Data Offer Alternatives for Patients With Lower-Risk MDS

March 23rd 2023

Frontline treatments that achieve transfusion independence are of paramount importance for patients with lower-risk myelodysplastic syndrome.

Newly Defined Breast Cancer Targets Expand TNBC Treatment Options

March 23rd 2023

Kevin Kalinsky, MD, MS, discusses genetic sequencing in triple-negative breast cancer, the significance of breast cancer tumor board discussions for informing further research and optimizing patient care, and how future directions in breast cancer treatment are building off the current benefits of drugs classes like antibody-drug conjugates.

First-line Zolbetuximab Plus CAPOX Prolongs Survival in CLDN18.2+/HER2– Unresectable Locally Advanced or Metastatic Gastric/GEJ Adenocarcinoma

March 22nd 2023

The addition of zolbetuximab to CAPOX led to a statistically significant improvement in progression-free survival and overall survival compared with placebo plus CAPOX for patients with Claudin-18.2–positive/HER2-negative, unresectable, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.

Erdafitinib Elicits Responses in High- and Intermediate-Risk NMIBC Harboring FGFR3/2 Alterations

March 22nd 2023

Siamak Daneshmand, MD, shed light on the phase 2 THOR-2 study evaluating different cohorts of patients with recurrent NMIBC, key findings from cohorts 2 and 3, and how ongoing research seeks to move the needle forward with novel drug delivery methods.

Spotlight on a Rare Hematologic Disorder: Hereditary Hemorrhagic Telangiectasia

March 22nd 2023

Hematologists and oncologists are uniquely poised to aid in the identification of patients with hereditary hemorrhagic telangiectasia and assist in their care, and it is important for the practicing clinician to familiarize oneself with the symptoms of hereditary hemorrhagic telangiectasia to avoid overlooking the diagnosis.

FDA Approves Retifanlimab for Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma

March 22nd 2023

The FDA has approved retifanlimab-dlwr (Zynyz) for the treatment of adults with metastatic or recurrent locally advanced Merkel cell carcinoma.

Florida Cancer Specialists & Research Institute Television Commercial Recognized with Silver ADDY® Award

March 22nd 2023

A television commercial produced by Florida Cancer Specialists & Research Institute, LLC has been recognized with a Silver ADDY® by the American Advertising Awards, which honors excellence in advertising as judged by creative industry professionals around the world.

Disadvantaged Neighborhoods, Modifiable Chronic Health Conditions Are Associated With Late Deaths in Survivors of Childhood Cancer

March 22nd 2023

Living in a socioeconomically disadvantaged neighborhood or living with modifiable chronic health conditions were associated with an increased risk for death 5 years of more following diagnosis among survivors of childhood cancer, according to findings from a cohort study.

CAR T-Cell Therapy for Multiple Myeloma: Eliminating Disparities Through Accountability

March 22nd 2023

Although the first FDA approval for CAR T-cell therapy in multiple myeloma was 2 years ago, unfortunately, the treatment remains out of reach for too many patients.